Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.030
0.00 (0.00%)
At close: Sep 18, 2026, 4:00 PM EDT
1.040
+0.010 (0.97%)
After-hours: Sep 18, 2026, 8:00 PM EDT
Lineage Cell Therapeutics Employees
As of December 31, 2025, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees did not change compared to the previous year.
Employees
77
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$169,909
Profits / Employee
-$418,961
Market Cap
260.49M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 77 | 0 | - | 72 | 5 |
| Dec 31, 2024 | 77 | 2 | 2.67% | 70 | 7 |
| Dec 31, 2023 | 75 | -3 | -3.85% | 68 | 7 |
| Dec 31, 2022 | 78 | 17 | 27.87% | 70 | 8 |
| Dec 31, 2021 | 61 | 6 | 10.91% | 57 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Bicycle Therapeutics | 288 |
| ProQR Therapeutics | 187 |
| Lyell Immunopharma | 161 |
| Sutro Biopharma | 128 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| Sionna Therapeutics | 59 |
LCTX News
- 11 days ago - Lineage Cell announces issuance of patent underlying AlloSCOPE 5D platform - TheFly
- 11 days ago - Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform - Business Wire
- 26 days ago - Lineage Cell Therapeutics management to meet with B. Riley - TheFly
- 6 weeks ago - Lineage Cell Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - Lineage Cell Therapeutics Earnings release: Q2 2026 - Filings
- 6 weeks ago - Lineage Cell Therapeutics Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Lineage Cell Therapeutics reports Q2 EPS (3c), consensus (3c) - TheFly
- 6 weeks ago - Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire